Introduction
The Philadelphia chromosome is the most frequent single recurrent cytogenetic abnormality in adult acute lymphoblastic leukemia (ALL) and together with t(4;11) rearrangement is the most adverse prognostic factor in these patients. 1, 2 The former carries the BCR-ABL fusion gene, which encodes the p190 BCR-ABL and p210 BCR-ABL oncoproteins that are targeted by the tyrosine kinase inhibitor, imatinib.
Concurrent or alternating use of imatinib together with intensive chemotherapy for remission induction and consolidation is associated with a high frequency of morphologic (95%-100%) and molecular (50%) CR [3] [4] [5] [6] [7] [8] in young adults with Philadelphia chromosome-positive ALL (Ph + ALL). These features have translated into a survival probability which is significantly higher than that obtained in historical controls with similar chemotherapy schedules without imatinib. Consequently, the combination of imatinib and chemotherapy is considered the standard treatment of Ph + ALL. 9 In young patients with a histocompatible donor, allogeneic stem cell transplantation (SCT) is usually recommended in first CR when feasible, especially in patients with negative or low minimal residual disease (MRD) or, alternatively, immediately after detection of disease at the molecular level. However, with prolonged follow-up a substantial proportion of young patients and practically all the elderly patients relapse. [10] [11] [12] Some of the relapses are late, making careful molecular follow-up of these patients mandatory.
There is scarce information on the feasibility and efficacy to prevent relapse of imatinib given as maintenance therapy after SCT in patients already treated with imatinib and chemotherapy before SCT. Uncontrolled studies 13 or ongoing clinical trials 14 indicate that imatinib administration is feasible, with a low relapse rate and an acceptable transplant-related mortality (TRM) but tolerability may lead to early discontinuation or limit dose intensity of imatinib in some patients. On the other hand, the need for the administration of this drug in patients without residual disease after SCT, the optimal duration of imatinib treatment and the feasibility and the efficacy of the combination of imatinib with other agents as maintenance therapy are unknown. 9 We undertook a prospective phase II study to evaluate the efficacy of concurrent administration of imatinib and intensive chemotherapy during remission induction and consolidation, and the feasibility and efficacy of imatinib after SCT in a series of 30 patients with newly diagnosed Ph + ALL.
Design and Methods

Eligibility
Patients up to 65 years of age with newly diagnosed Ph + ALL were eligible for the CSTIBES02 study if they showed Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, adequate renal and hepatic function (serum creatinine < 152. 5 
Study design and therapy
This was a prospective, nonrandomized, phase II trial conducted by the Spanish PETHEMA (Programa Español de Tratamiento en Hematología) and GETH (Grupo Español de Trasplante Hemopoyético) groups. The protocol was reviewed and approved by the institutional review board of each of the participating centers and was conducted in accordance with the Declaration of Helsinki. Patients provided written consent before entering the study. The trial was registered at http://www.clinicaltrials.gov as NCT00388895.
The treatment schedule is depicted in Table 1 . Remission induction therapy consisted of weekly vincristine (VCR) and daunorubicin (DNR), and daily prednisone (PDN) and imatinib (400 mg/d from day 1). Bone marrow aspiration was performed on day 15. Patients with standard response (less than or equal to 5% of blast cells or hypocellular bone marrow) continued with the same schedule up to day 28. Those with slow response (more than 5% blast cells) received mitoxantrone (MTZ) and cytarabine (AraC) together with imatinib (Table 1) . Patients who did not attain CR were considered as failures and were excluded from the study.
The first consolidation cycle (C1) consisted of highdose methotrexate (MTX), mercaptopurine (MP), highdose ara-C, teniposide (VM26) and imatinib (400 mg/d), and the second consolidation cycle (C2) included VCR, DNR, dexamethasone (DXM), cyclophosphamide (CTX) and imatinib (400 mg/d) ( Table 1) .
For the initiation of each consolidation course, full hematological recovery described as neutrophil counts of at least 1x109/L and platelet counts of at least 50x109/L were required. Central nervous system (CNS) prophylaxis was performed by intrathecal injection of MTX (15 mg), AraC (30 mg) and hydrocortisone (20 mg) during the remission induction cycle (days 1 and 22), C1 (days 1, 28 and 56) and C2 (days 1 and 15). Patients with evidence of CNS leukemia at diagnosis (5 or more leukemic blasts/mL ensuring no sample contamination by peripheral blood) received intrathecal injections two times a week until the findings disappeared on two consecutive cerebrospinal fluid (CSF) examinations. C2 cycle was not mandatory if a donor was already available.
After C2, patients with a HLA-identical donor were submitted to allogeneic SCT. The remaining patients, as well as those with medical contraindications for allogeneic SCT, received an autologous SCT. Mobilization with G-CSF was carried out after recovery from C2 cycle After SCT imatinib (400 mg/d) was scheduled in all patients from full hematologic recovery up to a minimum of one year if molecular remission persisted.
The preparative regimen for autologous or allogeneic SCT (either from an HLA-identical sibling or from an unrelated donor) consisted of fractionated total body irradiation (TBI) (total dose 13 Gy, from day -7 to -4), and CTX (60 mg/kg days -3 and -2). For patients aged over 50 years non myeloablative conditioning regimen with fludarabine (30 mg/m2, from day -8 to -4) and melphalan (70 mg/m 2 , days -3 and -2) was recommended. For the cases in whom unrelated cord blood (UCB) was the source of hemopoietic stem cells, the recommended schedule for conditioning included tiothepa (5 mg/kg days -7 and -6), fludarabine (50 mg/m2, days -5, -4 and -3), busulphan (3.2 mg/Kg in intravenous infusion days -5, -4 and -3) and thymoglobulin (2 mg/Kg days -5, -4, -3 and -2).
Dose modifications
In patients aged 60 years or older AraC was reduced to 500 mg/m2 every 12 hours in the induction therapy and MTX was reduced to 0.75 g/m 2 in the C1 cycle. Dose modification of imatinib was generally based on the following conditions. During remission induction and consolidation courses, dose reduction or interruption of imatinib for hematologic toxicity was not essentially considered and for grade 3 or 4 nonhematologic toxicity administration was interrupted until recovery to grade 1 or better and then resumed at 400 mg/d. If grade 3 or 4 toxicity recurred after resuming imatinib, a dose reduction to 300 mg and 200 mg was implemented. Imatinib was not to be interrupted during the interval between induction and consolidation cycles or between the two consolidation courses or during the mobilization and collection of hematopoietic stem cells. The administration of imatinib was interrupted 15 days before SCT and was resumed after full hematologic recovery was achieved. If imatinib-related toxicity or intolerance appeared in the post-SCT setting, dose reductions to 300 mg and 200 mg were allowed before permanent discontinuation.
Supportive care
Hospitalization, prophylaxis and management of infections and transfusion policy were performed according to the specific protocols of each participating hospital. Granulocyte colony stimulating factor (G-CSF) (5 mg/kg/d, SC) was administered in all cases in which neutropenia developed following the induction and consolidation cycles. In cases of autologous or allogeneic SCT, G-CSF was administered from day +7 until sustained neutrophil recovery over 1x10 9 /L was achieved.
Evaluation of patients
The primary objectives of this study were to assess the CR rate, the proportion of patients reaching SCT in the first molecular CR and the feasibility and efficacy of imatinib after SCT. The secondary aims were to assess the toxicity and safety of the therapy, response duration and survival. Pretreatment evaluations included clinical history and physical examination, complete blood count with differential, Sequential Multiple Analysis-12, and bone marrow aspiration for cytology, flow cytometry and cytogenetic studies. Marrow aspirations were repeated on day 14 after the onset of therapy, at the time of CR evaluation (usually on days 28 to 35 after the beginning of chemotherapy), before the C2 cycle, before the SCT, and every 3 months after SCT.
Quantitative real-time polymerase chain reaction (RT-PCR) assays for BCR-ABL with TaqMan technology were centrally performed on BM and PB samples according to the guidelines approved in the Europe Against Cancer Program (EAC), in a central laboratory participating in this program. 15 Standard curves were produced for major and minor BCR-ABL breakpoint variants doing 10-fold dilution series of five different plasmid concentrations (200,000, 20,000, 200, 20 and 2 copies/mL). To minimize the variability in the results due to differences in the efficiency of cDNA synthesis and RNA integrity among the patient samples, the 
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absolute BCR-ABL copy number was normalized to the expression of the GUS gene (housekeeping gene) chosen according to the ECA program 16. The normalized values of the BCR-ABL copies in each sample were reported as BCR-ABL number of copies. All experiments were carried out in duplicate. At least 105 GUS plasmid equivalents were required in a sample to consider a negative PCR result valid; otherwise, the sample was not useful for minimal residual studies. All reactions were performed on an ABI PRISM 7700 DNA Sequence Detection System (Applied Biosystems, Foster City, CA, USA). Fluorescence spectra were continuously monitored and analyzed by the SDS system (Applied Biosystems, software version 1.9). Samples were collected at diagnosis, at day 14 of remission induction therapy, at the time of CR evaluation, following the C1 cycle, before SCT and every 3 months after SCT. Negative results were not confirmed by nested PCR. Concurrent detection of minimal residual disease (MRD) was performed by multiparametric flow cytometry (FACScan, Becton/Dickinson Biosciences, San José, CA, USA) in the same BM sample and laboratory using quadruple staining, as previously described.
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Briefly, erythrocyte-lysed whole BM samples were stained with an identical panel of four-color (FITC, PE, PerCP-Cy5, APC) combinations of monoclonal antibodies (MoAb) aimed at the specific identification of blast cells 18, as follows: CD10/CD20/CD19/ CD34, CD10/CD19/CD38/CD34, CD10/CD34/ CD19/CD45, CD10/ CD13/CD19/ CD34, and CD10/CD33/CD19/CD34.
All MoAb were purchased from Becton Dickinson. In order to increase the sensitivity of the analysis, data acquisition in the flow cytometer for follow-up samples was performed in two consecutive steps. Briefly, in the first step, acquisition of all the cells present in the sample was performed and at this point at least 20,000 events/tube were measured. Subsequently, in a second step, a multiparametric live-gate was used to acquire more data specifically on leukemic cells potentially present at low frequencies in the sample. For that purpose, acquisition through a low to intermediate SSC/CD19 + and SSC/CD34 + antigen live gate was performed and information was collected for at least 105 BM nucleated cells. Data analysis was based on the identification of cells with aberrant phenotypic features 18. For data acquisition, either the LYSIS II or CellQuest software programs (Becton Dickinson Biosciences) were used. The PAINT-A-GATE PRO software program (Becton Dickinson Biosciences) with the polynomial SSC transformation capability was used for further data analysis.
Toxicity was evaluated on the basis of the National Cancer Institute Expanded Common Toxicity Criteria (NCI-TCT) version 2.0. Studies on ABL kinase domain mutations were not routinely performed.
Response criteria
Complete remission (CR) was defined as all of the following: less than 5% blasts in BM, no leukemic blasts in PB, recovery of PB values to neutrophil counts of at least 
Statistical analysis
Disease-free survival (DFS) was measured from the date of CR until documented relapse or death in remission of any cause. Overall survival (OS) was measured from the date of initiation of therapy until death of any cause. Transplant-related mortality (TRM) was defined as death occurring after SCT in relapse-free patients. DFS and OS curves were plotted according to the methods of Kaplan and Meier 19 with differences analyzed by the log-rank test 20. Patients undergoing SCT were not censored at the time of transplantation. The Statistical Package for Social Sciences (SPSS) 12.0 software (SPSS, Chicago, IL, USA) was used for all statistical analyses. Table 2 . The p190 BCR-ABL transcript (e1a2) was expressed in 23 (80%) of the 30 patients and p210
Results
Patient characteristics
BCR-ABL (b2a2 or b3a2) in the remaining 7 (20%). The median age of the group was 44 years and there was only one patient under 15 years and 2 over 60 years of age; 16 patients (53.3%) were males. 
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Treatment efficacy Figure 1 shows the progression of the patients along the trial. Twenty-seven (90%) of the 30 patients achieved CR. This CR rate is higher than that observed in the ALL93 trial (70%, p=0.045), which included the same chemotherapy without imatinib. One patient had resistant leukemia and two patients died in the remission induction period due to infection. Of the 27 patients who achieved CR, 20 had a standard response at day 14 and the remaining 7 had a slow response. One patient was removed from the study before C1 due to disseminated CNS tuberculosis. Twenty-six patients received the first consolidation cycle (C1) and 15 the second one (C2). One patient died after the C1 cycle due to infection. Four patients relapsed before SCT, two of them after C1 and two after C2.
Transplantation outcome
SCT (allogeneic, 16; autologous, 5) was performed in 21 out of 27 (78 %) CR patients. The median time from CR to SCT was 187 days (range 129 to 297 days). Conditioning regimens included CTX and TBI (n=16), and tiothepa, fludarabine, busulphan and thymoglobulin in the three patients receiving an unrelated cord blood, and a reduced intensity regimen with fludarabine and melphalan in two additional patients. Donor consisted of an HLA identical sibling in 8 patients, and an alternative donor in 8 cases, including three cases of UCB. All patients achieved successful engraftment. Non-relapse TRM occurred in 8 patients after related donor SCT (n=2), after non myeloablative related donor SCT (n=2), after MUD SCT (n=2) and after autologous SCT (n=2). The main causes of death in these patients included early death before hematologic recovery (2), graft versus host disease (GVHD)(4), post-transplant lymphoproliferative disorder (1) and pneumococcal pneumonia after complete post-SCT hematological recovery (1 auto-SCT patient). Five patients relapsed in bone marrow (n=4) or in bone marrow and CNS (n=1) between 5 and 27 months following SCT (4 allogeneic and 1 autologous).
Minimal residual disease measurements
Levels of marrow quantitative RT-PCR positivity under 50 copies occurred in 6 out of 29 (21%) evaluable patients on day 14 and in 24 out of 28 (86%) patients at the time of CR (Figure 2 ). The median BCR-ABL copy numbers decreased 1 log on day 14 with an additional 2 log reduction at the time of CR. In turn, levels of MRD under 0.01% by flow cytometry were observed in 5 out of 29 (17%) patients on day 14 and in 12 of 28 (43%) evaluable patients at the end of induction (Figure 3) . Similar to the PCR study, there was also a median 3 log reduction in the level of MRD during the remission induction period. There was an additional mean reduction of 2 logs in residual disease before the onset of C2. PCR negativity before C2 was observed in 11 out of 26 (42%) patients and MRD negativity by flow cytometry was registered in 15 out of 26 (58%) cases. PCR negativity and MRD negativity by flow cytometry before SCT were observed in 15 out of 23 (65%) patients and 14 out of 23 (61%), respectively. No significant reduction was observed in MRD between the onset of C2 and the time of SCT. After SCT, complete molecular response was achieved in 15 out of 19 patients (79%) by RT-PCR and 17 out of 19 patients by flow cytometry (Figures 2 and  3 ). All patients presenting molecular CR before and after SCT by both techniques (n=6) remained in continuous 
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CR at last follow-up. Inversely, detection of less than major response before or after SCT by any of the two techniques was invariably associated with relapse. Post-SCT major response was associated with relapse only if PCR and flow cytometry were concordant. One log increase in MRD both before and after SCT was predictive of relapse by either technique. Among patients undergoing an autologous SCT only one was MRD-positive before the procedure and relapsed early afterwards, none of the other 4 relapsed although 2 died of other causes.
Imatinib after stem cell transplantation
Imatinib was started following SCT in 13 out of 21 patients (62%), the median time from SCT to initiation of imatinib being 3.9 months. Four out of five patients who had received an autologous SCT could start imatinib maintenance that could be continued up to last control (n=2, 40 and 60 months) or death (n=2). The remaining patient did not start therapy due to persistent severe thrombocytopenia after the procedure followed by early post-SCT relapse. The main reasons for not initiating imatinib among patients submitted to an allogeneic-SCT were early TRM (n=4, including the patient with posttransplant lymphoproliferative disease), severe GVHD (n=1) and patient decision (n=2). The median time on imatinib therapy for the remaining 9 patients submitted to an allogeneic SCT was 9 months (range 1 to 27). Post-SCT reductions up to 200 mg occurred in 3 patients (2 were able to continue imatinib treatment to last control and another patient had to discontinue treatment). Imatinib was interrupted due to relapse (n=3), severe chronic GVHD (n=2), grade 3-4 toxicity (n=2, hematologic in one patient and gastrointestinal in the remaining), non-relapse TRM (n=1) and patient abandon (n=1) after 24 month of continuous imatinib treatment.
Survival
Nine patients remain alive after 3 years of follow-up, 8 in complete molecular response and 1 in molecular relapse. After a median follow-up of 4.1 yr (range 3.9-4.8), the DFS and OS medians were 1.5 yr and 1.7 yr., respectively, and the probabilities of DFS and OS were of 30% (95% CI 16% to 45%) and 30% (95%CI 15% to 45%), respectively. (Figure 4) . The survival was significantly better than that from the historical cohort of 37 patients included in the ALL93 trial including chemotherapy and SCT without imatinib (Online supplementary figure 1 ). Table 3 shows the hematologic toxicity during the induction and consolidation periods. Grade III-IV neutropenia was observed in almost all induction cycles, especially in patients receiving intensified induction. The frequency and duration of severe neutropenia was lower after the C1 and C2 cycles. The frequency of severe thrombocytopenia throughout the study was 
Toxicity
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low and no cases of severe thrombocytopenia were observed in the C2 cycle. Grade III-IV non-hematological toxicity is shown in Table 4 . Infections, especially bacterial, followed by hepatic and gastrointestinal toxicity were the most frequent adverse events. Other frequent grade I-II toxicities were hepatic, fluid retention, mucositis and wasting syndrome. No major toxic events were observed during the mobilization of peripheral blood hematopioetic stem cells (HSC), either for autologous SCT (5 cases) or as a back-up prior to an unrelated donor or UCB SCT (8 cases). During this period the patients continued on imatinib therapy and the collection of HSC was adequate in all cases.
Interruption of post-SCT imatinib maintenance was directly associated with imatinib in 2 out of 10 patients (one each gastrointestinal and hematological grade 3 toxicity) and a likely association with imatinib and other drugs was established in another case (microangiopathic thrombocytopenia). No other grade 3 or more toxicity attributed to imatinib was recorded.
Discussion
The results of this study confirm that imatinib is an effective first-line treatment for de novo adult Ph+ ALL when given concurrently with chemotherapy and allows SCT to be performed in a substantial proportion of patients in major or complete molecular remission. However, in the present trial prophylactic imatinib could not be given as scheduled after SCT in an important proportion of patients mainly due to transplantrelated events. Imatinib specific toxicity was not an issue for most patients and, particularly in the autologous SCT setting could be administered safely for a prolonged period of time. As occurred in other contemporary trials, combining chemotherapy and imatinib (in concurrent or intermittent schedules) improved the results in terms of cytologic and molecular CR, [3] [4] [5] [6] [7] [8] 21 time to hematological response and survival with respect to historical controls of chemotherapy without imatinib. [22] [23] [24] It is of note that the clearance of MRD was mainly observed during the induction and the first consolidation cycle (C1), with no further decrease thereafter. The fact that 2 out of the 4 patients from the present study who relapsed before SCT did so after the C2 cycle raises the question as to whether an earlier SCT would have avoided such relapses. Both flow cytometry and molecular biology appeared to be highly predictive of both pre-SCT (4 out of 8 patients relapsing before SCT when MRD > 0.01 % after C1) and post-SCT relapse (5 out of 5 relapsed at any level of detectable MRD). As a result of an improved CR rate, 50% to 86% of patients 
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with Ph + ALL could be submitted to allogeneic SCT in first CR in several trials combining imatinib and intensive chemotherapy 3-5, 21. We used a relatively low dose of imatinib (400 mg/day) to ensure continuous treatment during initial tratment obtaining similar short-term results (CR rate, molecular remision rate at the end of induction and proportion of cases submitted to allogeneic SCT in a MRD negative status) to contemporary trials giving imatinib at a dose of 600 mg/day.
No definitive consensus has been reached on the need to systematically perform allogeneic SCT in patients with good molecular response. 9 In our study SCT (allogeneic when possible) was scheduled for all of the patients in CR and was actually performed in 74% of them. It is of note that 65% or 61% (PCR or flow cytometry) of the patients in our series were in complete molecular remission at the time of SCT. There is evidence that the quality of remission before SCT is associated with a lower probability of post-transplant relapse.
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Despite encouraging short-term results, relapses are observed in a very significant proportion of patients treated with the combination of imatinib an chemotherapy, even after allogeneic SCT resulting a drop in the probability of survival down to 30%-50%10,11 in cohorts with an extended follow-up, as occurred in the present trial, which is one with the most prolonged follow-up reported to date. The occurrence of relapses after SCT provides the rationale to evaluate the usefulness of maintenance therapy. There is evidence suggesting no detrimental effects of pre-SCT imatinib on engraftment, GVHD occurrence and severity or on transplant-related organ toxicity. Uncontrolled studies have shown that imatinib can also be safely administered early after myeloablative allogeneic SCT at a dose intensity comparable to that used in primary therapy, 13, 29 and there is preliminary evidence that imatinib can also be administered safely after autologous SCT. 30 In the study of Wassmann et al., 26 half of the patients with Ph + ALL receiving imatinib for MRD positivity after SCT experienced prolonged DFS, which could be anticipated by the rapid achievement of molecular CR. This makes imatinib a good candidate for maintenance therapy after SCT, with the objective of preventing relapses, although the need for systematic administration of imatinib after allogeneic SCT has not been adequately addressed yet. An ongoing randomized trial by Wassmann et al 14 recently updated is comparing systematic versus MRDtriggered administration of imatinib after SCT and the preliminary results show a low rate of relapses in both arms, suggesting that the administration of imatinib early after molecular relapse is equally effective as the systematic administration of that drug as long as a close molecular follow-up of patients after SCT is ensured (i.e.: every 3 weeks). However, imatinib was discontinued in 48% of cases mostly due to gastrointestinal toxicity and GVHD. The impact of allogeneic SCT toxicity was even more striking in the present trial, accounting for a significant proportion of non-relapse mortality and significantly limiting post-SCT exposure to imatinib. The relatively high TRM may explain the slightly lower survival observed in our study in comparison with other similar trials.
3-8,21
Given the frequency of ABL domain mutations in young 27 and elderly 28 patients with Ph + ALL at diagnosis, second generation tyrosine kinase inhibitors (dasatinib, nilotinib) may have been alternative candidates for prophylactic post-SCT treatment. Although no ABL mutation studies were performed in the present trial, our results suggest that, in the post-SCT setting, tolerance to treatment rather than emergence of resistant clones, is the main issue.
Inferences on the influence of imatinib in TRM cannot be made from the results of our trial, although this influence is not likely. Imatinib was well tolerated during induction and consolidation and post-SCT. Early transplant-related mortality and GVHD were the major causes of inability to start or continue post-transplant imatinib maintenance. In fact, exposure to imatinib was minimal in a substantial proportion of patients submitted to allogeneic SCT mainly due to transplant-related events. The heterogeneity of circumstances of patients reaching SCT, particularly their differences in MRD-status, in the available source of stem cells and ultimately in post-SCT complications, imposes an important limitation to interpretation of results. Nevertheless, interruption of imatinib maintenance because of imatinib toxicity was rare, being allo-SCT complications the main cause of imatinib suspension. In our trial the two patients with the longest duration of imatinib exposure had been submitted to autologous SCT. In this regard, lymphocyte-depleted allogeneic SCT or even autologous SCT appear as sensible alternatives if imatinib maintenance is to be attempted. Whether imatinib maintenance is capable of compensating the low graftversus-leukemia effect of an undepleted graft remains an open question that can only be answered by specifically designed trials. The significant proportion of patients obtaining molecular remission before-SCT and a greater possibility of maintaining imatinib therapy in the patients submitted in our trial would argue in favor of such strategies. Unfortunately, the number of patients submitted to an autologous-SCT in our trials was too small to draw any strong conclusion.
In summary, our trial confirms the efficacy of therapy programs combining intensive chemotherapy, imatinib and SCT. However, we have shown that the systematic administration of imatinib early after allogeneic SCT presents major limitations due to transplant-related events. Once imatinib is given, discontinuation is frequent, again due to transplant-related events rather than imatinib toxicity. These should be taken into account when planning to give maintenance therapy with imatinib or with other thyrosine kinase inhibitors, either alone or in combination, after allogeneic SCT. An autologous SCT might be an adequate alternative approach, worth being explored in specifically designed trials.
